New Analyst Forecast: $ELEV Given 'Neutral' Rating

ELEV received a 'Neutral' rating from H.C. Wainwright, adding to the recent analyst activity which includes one 'Outperform' rating from William Blair. Institutional investment in ELEV shows mixed sentiment, with 32 investors increasing positions, notably BML CAPITAL MANAGEMENT adding 5,890,934 shares, while 43 decreased holdings, including complete exits by FARALLON CAPITAL MANAGEMENT LLC, BVF INC/IL, and HUDSON BAY CAPITAL MANAGEMENT LP.

Analysis

Elevation Oncology ($ELEV) has received a 'Neutral' rating from H.C. Wainwright, contributing to a nuanced analyst outlook that also includes an 'Outperform' rating issued by William Blair on January 3, 2025. Overall, one firm maintains a buy rating on $ELEV, with no sell ratings reported from Wall Street analysts. Institutional activity in the most recent quarter indicates a net divestment trend, as 43 investors reduced their positions while 32 increased theirs. A significant new investment was made by BML CAPITAL MANAGEMENT, LLC, which added 5,890,934 shares, valued at approximately $1.53 million, in Q1 2025. However, this was contrasted by substantial liquidations in the same quarter: FARALLON CAPITAL MANAGEMENT LLC sold 3,527,482 shares (-100.0%), BVF INC/IL sold 2,966,836 shares (-100.0%), GOLDMAN SACHS GROUP INC reduced its stake by 1,575,077 shares (-95.4%), and RENAISSANCE TECHNOLOGIES LLC cut its position by 956,009 shares (-59.6%). Further exits in Q4 2024 included HUDSON BAY CAPITAL MANAGEMENT LP (1,359,246 shares, -100.0%) and PALO ALTO INVESTORS LP (1,298,097 shares, -100.0%). This pattern of institutional selling, particularly the complete exits and significant reductions by several funds, aligns with the provided mildly negative general sentiment score (-0.25) and a specific per-ticker sentiment of -0.4 for $ELEV, suggesting a cautious institutional stance despite some isolated bullish conviction.

Key Decisions for Investors

• Investors should acknowledge the mixed signals for $ELEV, including a new 'Neutral' analyst rating and significant net institutional selling, juxtaposed with an existing 'Outperform' rating and one substantial new institutional investment.
• Closely monitor upcoming institutional holding reports, particularly for Q2 2025, and any further analyst rating changes for $ELEV to identify emerging consensus or shifts in sentiment.
• Exercise caution due to the notable complete exits and substantial position reductions by several institutional investors; carefully evaluate the risk-reward profile and consider the prevailing negative sentiment before increasing exposure to $ELEV.